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INTRODUCTION: 
The interest of pharmaceutical companies is increasing in 
the field of shelf life management, as it plays an important 
role in success of any formulation/ drug delivery 
technology.1-2Drug delivery technologies which pose 
significant advantages over first generation commercial 
products provide an important means for staying 
competitive in today’s growing and challenging business 
scenario.3-4 A superficial glance through the scientific and 
patent literature divulges that it is replete with examples in 
which decreasing the particle size of an active 
pharmaceutical ingredient (API) results in increased 
solubility and subsequent bioavailability.5In the case of 
formulations intended for oral administration, poorly water 
soluble APIs may suffer from an inadequate rate and 
extent of drug absorption. Before formulating, the particle 
size reduction of API will significantly increase the 
specific surface area, saturation solubility, dissolution rate 
and finally bioavailability in gastrointestinal fluid.6 
Therefore in the case APIs of BCS Class II and Class IV as 
per biopharmaceutical classification system, absorption is 
dissolution limited so decreasing the particle size may 
result in significant improvement in the rate and extent of 
drug absorption such that the bioavailability requirements 
of the drug candidates are met.7-9Leading drug delivery 
technologies employing proprietary milling process that 
have produced nanotechnology integrated products such as 
Nanocrystal® from Elan Drug Technologies, insoluble 
drug delivery (IDD
®
) technology from Skye Pharma, 
Biorise® technology from Eurand and NanoEdge® 
technology from Baxter Biopharma Solutions.10-
13Nanocrystal technology has been the front runner that 
forms the technology platform for four marketed products 
in USA. Particle size can be decreased by various 
approaches but, subsequently in formulation, the API is 
usually dispersed in either aqueous or non-aqueous 
medium depending upon the pharmaceutical applications. 
Preparation of a stable formulation requires that a non-
agglomerating and reproducible particle size distribution 
(PSD) should be achieved. This requires not only proper 
dispersion of the particles but also subsequent prevention 
of any re-agglomeration. Proper dispersion greatly 
enhances final product performance as well as maximizes 
efficiency and provides better product value from raw 
materials. 
 
a. Primary particle  b. Aggregates  c. Agglomerates 
Figure 1: Size nature of dry particles 
Although having good formulation skills, experience and 
testing, problems can still sometimes be encountered in 
achieving stable, effective and elegant formulations 
containing nanoparticles. It is simply a matter of proper 
technique to disperse powders in liquids, based on an 
understanding of a few key principles. By considering each 
component of the disperse system in relation to the whole, 
logical choices can be made that will produce the 
anticipated product. All powders comprise three groups of 
particles: primary particles, aggregates and agglomerates. 
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These three distinct species constitute what is known as the 
PSD of any nanoparticulate formulation.  
 
Figure 2: Relationship between different particle groups 
The process of dispersion requires overcoming the various 
binding forces between particles by use of both 
physiochemical and mechanical means. The final dispersed 
state is accomplished via three distinct steps: wetting the 
solid surface, de-agglomeration of the particles and 
stabilization of the particles. It is crucial that these three 
steps be viewed as distinct and are performed in correct 
order. This is not to say that all three steps always require 
separate procedures but, the procedures must occur in 
sequence. In addition, the following factors will play an 
important role too. 
 Selection of the liquid medium for particulate 
dispersion. 
 Selection of the type and concentration of the various 
dispersion aids i.e. wetting agents, de-agglomerating 
agents and stabilizing agents. 
 Selection of the type and duration of the mechanical 
dispersing treatment. 
The complete dispersion process is shown in figure 3. Here 
each steps discussed separately in brief. 
 
 
A. Spreading and wetting         B. Deagglomeration   C. Steric stabilization 
Figure 3: Process of the dispersion 
SPREADING AND WETTING: 
After adhesion the liquids spreads around the dry 
nanoparticles and wet them. Wetting is the ability of a 
liquid to maintain contact with a dry particle/surface, 
resulting from intermolecular interactions when the two 
are brought together. The degree of wetting (wettability) is 
determined by a force balance between adhesive and 
cohesive forces.Wetting involves contact of the liquid 
medium to the solid surface of nanoparticles, spreading of 
the liquid over the surface and finally penetration of the 
liquid into the spaces between agglomerated particles. 
Term ‘lyophilic’ is used for the surfaces which are easily 
wetted, while those are difficult to wet are termed 
‘lyophobic’; such surfaces require the use of a wetting 
agent. Many APIs falls in the latter category. The 
fundamental thermodynamic equations which govern 
adhesion and spreading are expressed by followings.  
Spreading coefficient is expressed as  
S = γSG – (γSL + γLG) 
Young’s equation is expressed as  
γSG=γSL + γLGcosθ 
Combing the spreading coefficient with the Young’s 
equation yields Young–Dupré equation.  
S = γLG (cosθ – 1) 
Where γSGis the interfacial tension between the solid and 
the gas/vapor, γSLis the interfacial tension between the 
solid and liquid, γlGis the interfacial tension between the 
liquid and gas/vapor, θ is the contact angle at the solid – 
liquid interface and S is spreading coefficient. A surface 
will be completely wet when γLG, cosθ tend to zero and S > 
0. If the value of spreading coefficient is less than 0, there 
will be partial wetting.  
 
Figure 4: Forces acting on solid – liquid – gas (vapor) 
interface 
To achieve complete wetting it is essential to add a wetting 
agent to the liquid. A wetting agent adsorbs at the liquid – 
vapor interface, reducing the interfacial tension as well as 
the contact angle of the liquid at the surface of the 
particles. A wetting agent therefore termed as ‘surface 
active agent’ or ‘surfactant’. The absolute minimum of the 
surfactant should be used to achieve wetting. Higher 
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concentration of the surfactant will be increase the 
potential for foaming action rather wetting and this may 
lead the separation of the finer particles. An additional 
advantage of using the possible lowest concentration of the 
surfactant is to minimize any potential toxicity associated 
with it. 
 
Table 1: Relationship between degree of wetting, contact angle and interacting forces 
Degree of wetting Contact angle 
Strength of 
Cohesive forces at solid-
liquid interface  
Adhesive forces at liquid-
liquid interface 
Perfect wetting θ = 0 
Strong Weak 
Strong Strong 
High wettability 0 < θ < 90 Weak Weak 
Low wettability 90 ≤ θ < 180 Weak Strong 
Perfectly non wetting  θ = 180 Weak Strong 
 
It is also possible to pre-wet a surface without using a 
surfactant. Any liquid that has contact angle lower than 
water will be sufficient. For example ethanol and 
propylene glycol can be used at the place of water as 
wetting liquid. Liquid compounds having humectant nature 
(Glycerin,) will also work and should be considered to 
enhance wettability. The consequence of not achieving 
complete wetting is to affect the suspension properties, 
especially the stability. It is equally important to realize 
that if a solid wets its own (i.e. lyophilic particles) then a 
wetting agent is not required. In fact, the use of one may 
be makes the subsequent deagglomeration step more 
complex, which finally leads to an unstable system. 
DEAGGLOMERATION: 
When the liquid medium sufficiently wet the solid 
particles, the liquid starts to penetrate into the pores and 
capillaries between to particles and this tends to them 
arrange separately in the liquid medium. The rate of 
penetration is an important factor. It is desirable that this 
be as high as possible. An indication of the major variables 
which affects the penetration rate is expressed by the 
Washburn equation. 
L2 = (r t γLG/ 4η) 
Where L denotes the depth of penetration into a pore of 
radius (r) in time (t) and (η) is the viscosity of the liquid 
medium. In general, most of the wetting process (adhesion, 
spreading and penetration) is more spontaneous the lower 
the contact angle (θ) and higher the liquid – gas/vapor 
interfacial tension (γLG). Mostly all the surfactants affects 
both of these parameters, rendering the selection process of 
best agent for any system more difficult. 
The process of separation of particles from each other once 
they are wetted is termed as deagglomeration. A 
deagglomerating agent adsorbs only at the solid – liquid 
interface. Such substances are not ‘surface active’. Their 
job is to chemically aid separation of the agglomerated 
particles by increasing the electrostatic forces of repulsion 
between the particles. This allows further liquid 
penetration into the inter-particle spaces which ultimately 
enhance the separation process. For easily wetted material, 
this enhanced penetration of liquid into the void spaces 
between the particles may provide adequate force alone to 
bring about complete dispersion. The selection of the 
suitable deagglomerating agent requires consideration of 
both the particle’s surface chemistry and the dispersion 
medium conditions. For example taking water as the liquid 
medium, pH and electrolyte concentration also considered. 
Following initial wetting of the particles some mechanical 
agitation is needed. The degree of turbulence and shear 
vary considerably with the type of operation and design of 
the equipment. Essentially there are two processing 
methods, first is high shear mills in which efficiency 
depends on the formulation viscosity and secondly high 
impact mills in which efficiency depends on the size of the 
grinding media. A detailed overview on processing 
methods for the formulation of 
nanoemulsion/nanosuspensionand particulate dispersion 
systems can be find the different scholarly review and 
research articles. If however, the various steps previously 
discussed are followed, then the minimum of mechanical 
agitation will be adequate. Excess mechanical energy 
increases the thermal energy, and together they can be lead 
to re-agglomeration, alteration in PSD and subsequently 
the total available surface area. In addition, it is also 
possible to change in the surface chemistry. All of the 
abovementioned impinges on the specific properties of the 
suspension. 
STABILIZATION: 
Stabilization is the act of keeping the particles apart once 
they are wetted and deagglomerated. Essentially, it is the 
last step of the dispersion process. If completed too early, 
it just stabilizes agglomerates only. Hence, the order of 
addition of the ingredients is always of concern. 
Stabilization is usually accomplished via steric forces 
(adsorbed layers), electrostatic forces (surface charges) or 
a combination of both. Steric stabilization is preferred if 
the suspension is formulated in non-aqueous medium. 
‘Thickeners’ are often used to enhance the viscosity of the 
liquid. But it cannot be a substitute of true stabilization. 
Increasing the viscosity simply retard the sedimentation 
rate of the larger and/or denser particles. In any case 
thickeners should be incorporated after the stabilization 
step. As previously outlined the dispersion process is a 
series of orderly events, each reliant on the previous one. 
The performance of any system including pharmaceutical 
formulations is directly associated to this process. As 
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mentioned earlier, proper dispersion can greatly enhance 
the appearance and performance. As an example, the 
improved oral bioavailability of Elan Drug Delivery’s 
NanoCrystal technology formulation approach is based on 
the increased surface area of the nano milled APIs giving 
rise to increased dissolution rate of the 
NanoCrystalCollidalDispersion
TM
. However it is necessary 
to keep these nnaoparticles distinct in order to benefit from 
the enhanced surface area. This can be achieved by the use 
of both steric and electrostatic stabilization. This 
technology has been commercially validated and 
successfully used in many marketed products (i.e. First 
Horizon Pharmaceutical’s TriglideTM, Abbott’s Tricor®, 
PAR Pharmaceutical’s MEGACE® ES, Merck’s EMEND® 
and Wyeth’s RAPAMUNE®). Finally wet suspension can 
‘age’ on standing/storage or during shelf life, due to 
Ostwald ripening. Ostwald ripening is responsible for 
destabilizing all types of dispersions (suspensions, 
emulsions, foams, nanosuspension, nanoemulsions etc.). 
 
 
 
A. Un-stabilized particles: on contact, small particles with higher radial pressure feeds in larger particles 
 
B. Stabilized particle: smaller particle with higher radial pressure evaporates more molecules into the medium and larger 
particles with smaller radial pressure condenses molecules from medium 
Figure 4: Process of Ostwald ripening (4A & 4B) 
For dispersions, a critical parameter that determines if 
Ostwald ripening will occur is the solubility of the 
particular material in whatever liquid is chosen. Ostwald 
ripening only occurs for the substances that are sparingly 
soluble (BCS Class II/IV drugs); it does not occur if the 
substances are either completely soluble or completely 
insoluble. The consequence of Oswald ripening of 
suspension is that larger particles grow at the expense of 
the smaller ones. This increase on size can occur via two 
mechanisms. The first is that small particles ‘dissolve’ but 
because the solubility product is low, once sufficient 
material has dissolved and saturation is achieved any 
further dissolution results in nucleation followed by 
precipitation onto larger particles. The second mechanism 
occurs at higher particle concentrations. In this case, the 
smaller particles simply aggregate directly onto the surface 
of the larger particles which is thermodynamically, the 
preferred route. Thus Ostwald ripening is both solubility 
and concentration dependent and the rate of ripening is 
also depends on the viscosity of the suspending medium. 
CONCLUSION: 
This review elaborates the steps involved in the 
formulation of the particulate disperse systems. 
Knowledge of this process together with an understanding 
of the physical and chemical properties of the API is 
necessary to formulate pharmaceutically acceptable 
particulate disperse system. The aim is to tailor the 
resulting formulation to be stable during its entire shelf life 
and produce the desired pharmacological effect without 
any compromise. The formulation parameters that can be 
sightseen include particle size, surface charge or zeta 
potential and surface coating. Selection of wetting agent, 
deagglomerating agent, stabilizers and their concentration 
also plays an important role in the dispersion process and 
subsequently in the formulation of a stable product with 
adequate shelf life. Proper sequence of the different steps 
of the dispersion process is essential to produce a stable 
product, alteration in the sequence of the steps can lead to 
de-stabilization of the particulate suspension.  
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